Drug · CHEMBL3545280
EFATUTAZONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EFATUTAZONE. Drugs and targets, record CHEMBL3545280. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545280
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Phase 2, for 3 of its 4 diseases, from ClinicalTrials.gov and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor gamma agonist | AGONIST | https://conductscience.org/library/genes/5468 |
Source ChEMBL
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| non-small cell lung carcinoma | Phase 2 | ClinicalTrials.gov and TTD | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| colorectal cancer | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| myxoid liposarcoma | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0013280 |
| metastatic colorectal cancer | Phase 2 | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=EFO_1001480 |
Source Open Targets
Trials6
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01101334 | Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer | Phase 2 | 90 | 2020-06-16 | CS-7017 | The name of another form of it | ClinicalTrials.gov |
| NCT00986440 | Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy | Phase 2 | 84 | 2020-11-05 | CS-7017 | The name of another form of it | ClinicalTrials.gov |
| NCT00408434 | Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer | Phase 1 | 32 | 2020-10-19 | efatutazone | Its name | ClinicalTrials.gov |
| NCT01199055 | CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | Phase 1 | 16 | 2020-07-07 | CS-7017 | The name of another form of it | ClinicalTrials.gov |
| NCT01199068 | CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | Phase 1 | 15 | 2020-07-31 | CS-7017 | The name of another form of it | ClinicalTrials.gov |
| NCT00881569 | Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017 | Phase 1 | 2 | 2020-08-14 | CS-7017 | The name of another form of it | ClinicalTrials.gov |
Comparisons in its trials7
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CS-7017 Plus Erlotinib vs Erlotinib: Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy | 9 of 44 | 9 of 45 | 89 | NCT01101334 | Trial comparisons |
| CS-7017 Plus Erlotinib vs Erlotinib: deaths from any cause | 15 of 44 | 7 of 45 | 89 | NCT01101334 | Trial comparisons |
| CS-7017 Plus Erlotinib vs Erlotinib: serious adverse events | 24 of 44 | 16 of 45 | 89 | NCT01101334 | Trial comparisons |
| CS-7017 0.5 mg vs Placebo: deaths from any cause | 16 of 41 | 23 of 42 | 83 | NCT00986440 | Trial comparisons |
| CS-7017 0.5 mg vs Placebo: serious adverse events | 6 of 41 | 5 of 42 | 83 | NCT00986440 | Trial comparisons |
| CS-7017 0.50 mg BID vs CS-7017 0.75 mg BID: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT00881569 | Trial comparisons |
| CS-7017 0.50 mg BID vs CS-7017 0.75 mg BID: serious adverse events | 0 of 1 | 0 of 1 | 2 | NCT00881569 | Trial comparisons |
Papers from its trials1
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 22570147 | DERIVED | 1 |
Source PubMed
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3545280
GET https://conductscience.org/api/drugs/v1/CHEMBL3545280/targets